Abstract
Hydroquinone has pharmacological uses in disorders of pigmentation because of its ability to competitively inhibit the enzyme tyrosinase. Our contemporary review presents the strongest evidence supporting the use of hydroquinone with the most effective and tolerable formulations combining hydroquinone, retinoid and corticosteroid (modified Kligman formula or 'triple combination cream'). The risk of exogenous ochronosis is low if prescribed concentrations of ≤ 5 for a limited period with regular monitoring. Dermatologists should reassure patients that with controlled use, hydroquinone can be well-tolerated and safe for a range of hyperpigmentary conditions.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Clinical and Experimental Dermatology |
| Vol/bind | 46 |
| Udgave nummer | 4 |
| Sider (fra-til) | 636-640 |
| Antal sider | 5 |
| ISSN | 0307-6938 |
| DOI | |
| Status | Udgivet - jun. 2021 |